Rigel Pharmaceuticals Q3 EPS $(0.07) Beats $(0.13) Estimate, Sales $11.716M Miss $11.95M Estimate

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 50 percent increase over losses of $(0.14) per share

Benzinga · 11/05/2019 21:48

Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.13) by 46.15 percent. This is a 50 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $11.716 million which missed the analyst consensus estimate of $11.95 million by 1.96 percent. This is a 140.82 percent increase over sales of $4.865 million the same period last year.